Drug Profile

REGN 7999

Alternative Names: REGN-7999

Latest Information Update: 22 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regeneron Pharmaceuticals
Class Monoclonal antibodies
Mechanism of Action TMPRSS6 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Iron overload
Preclinical Beta-thalassaemia

Most Recent Events

30 Sep 2024 Phase-II clinical trials in Iron overload in Georgia (SC) (NCT06421636) (EudraCT-2023-508604-37-00)
13 Jun 2024 Pharmacokinetics and adverse events data from a phase I trial in Iron overload presented at the 29^th Congress of the European Haematology Association (EHA-2024)
20 May 2024 Regeneron Pharmaceuticals plans a phase II trial for Iron overload due to Beta thalassemia in September 2025 (SC) (NCT06421636) (EudraCT-2023-508604-37-00)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com